JanOne (Nasdaq: JAN), a US-based biopharmaceutical company, announced on Thursday that it has named John N Bonfiglio, PhD, as interim president of its JanOne Biotech subsidiary.

Dr Bonfiglio has served at Allergan Pharmaceuticals and Baxter HealthCare and then turned to discovering, promoting and leading smaller biotech ventures. He has served as CEO at Peregrine Pharmaceuticals. He has over 30 years of experience, with achievements including helping Cypress Bioscience reinvent itself as a neuro-pharmaceutical company and, as CEO of Immune Response Corporation, raising over USD50m and restarting clinical trials in HIV and MS. Presently, he is a board member for Avipero and executive board member for Sequella.

Tony Isaac, JanOne's CEO, said, 'We are delighted and honoured to have Dr Bonfiglio join us. His experience in running public biotech companies will prove invaluable to the progress of JanOne. Our entire team looks forward to working with him.'